Changes in Hong Kong stocks | Xianjian Technology (01302) rose more than 4% in the morning to absorb the peripheral dilatation stent system into the special review process for innovative medical devices

The Zhitong Finance App learned that Xianjian Technology (01302) rose more than 4% in the morning. As of press release, it rose 4.08% to HK$1.53, with a turnover of HK$29.5531 million.

According to the news, Xianjian Technology issued an announcement. The company received an official written notice from the China Drug Administration confirming that the ICS Elpis absorbable peripheral expansion film stent system independently developed by Yuanxin Technology (Shenzhen) Co., Ltd., a subsidiary of the company, has entered the China Drug Administration's special review process for innovative medical devices. This product is suitable for the treatment of common iliac artery and external iliac atherosclerotic stenosis or occlusive lesions. It is the company's 20th product to enter the National Drug Administration procedure.